Karen L. Smith

Merck & Co., Inc., Rahway, NJ, USA (United States)

Also affiliated with Johns Hopkins University, Massachusetts General Hospital, Sidney Kimmel Comprehensive Cancer Center

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 16 papers. Top paper: “Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer”.

Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer

New England Journal of Medicine(2023)10.1056/nejmoa2212856

N/A

4.5DataRank · unranked

216 citations

Samuel M. Niman, Monica Ruggeri, Fedro A. Peccatori, Hatem A. Azim, Marco Colleoni +34 more

Factors associated with worsening sexual function during adjuvant endocrine therapy in a prospective clinic-based cohort of women with early-stage breast cancer

Breast Cancer Research and Treatment(2022)10.1007/s10549-022-06750-w

N/A

0.569DataRank · unranked

6 citations

Amanda L. Blackford, Elissa Thorner, Jennifer Lehman, Claire Snyder, Vered Stearns +2 more

Adjuvant platinum versus capecitabine for residual, invasive, triple‐negative breast cancer: Patient‐reported outcomes in ECOG‐ACRIN EA1131

Cancer(2024)10.1002/cncr.35187

N/A

0.208DataRank · unranked

3 citations

Fengmin Zhao, Ingrid A. Mayer, Amyé Tevaarwerk, Sofia F. Garcia, Carlos L. Arteaga +20 more

Olaparib Use in Patients With Metastatic Breast Cancer Harboring Somatic BRCA1/2 Mutations or Mutations in Non-BRCA1/2, DNA Damage Repair Genes

Clinical Breast Cancer(2021)10.1016/j.clbc.2021.12.007

N/A

0DataRank · unranked

15 citations

Neha Mangini, John H. Fetting, Deborah K. Armstrong, Isaac S. Chan, Roisín M. Connolly +13 more

Further Evidence That OPG rs2073618 Is Associated With Increased Risk of Musculoskeletal Symptoms in Patients Receiving Aromatase Inhibitors for Early Breast Cancer

Frontiers in Genetics(2021)10.3389/fgene.2021.662734

N/A

0DataRank · unranked

14 citations

Karen L. Smith, Yuhua Zong, Christina L. Gersch, Andrea M. Pesch, Jennifer Lehman +6 more

The impact of weight loss on physical function and symptoms in overweight or obese breast cancer survivors: results from POWER-remote

Journal of Cancer Survivorship(2021)10.1007/s11764-021-01049-z

N/A

0DataRank · unranked

12 citations

Cesar A. Santa‐Maria, Amanda L. Blackford, David Lim, Ashley Carpenter, Karen L. Smith +6 more

Late effects in a high-risk population of breast cancer survivors

Supportive Care in Cancer(2021)10.1007/s00520-021-06597-9

N/A

0DataRank · unranked

2 citations

Sarah Skuli, Elissa Thorner, Nelli Zafman, Carol Riley, Jessica M. Ruck +6 more

A randomized phase III post-operative trial of platinum-based chemotherapy (P) versus capecitabine (C) in patients (pts) with residual triple-negative breast cancer (TNBC) following neoadjuvant chemotherapy (NAC): ECOG-ACRIN EA1131

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.605

N/A

0DataRank · unranked

7 citations

Fengmin Zhao, Carlos L. Arteaga, W. Fraser Symmans, Ben Ho Park, Brian L. Burnette +12 more

Reply to T. Shimoi et al and Y. Shimanuki et al

Journal of Clinical Oncology(2021)10.1200/jco.21.01905

N/A

0DataRank · unranked

2 citations

Fengmin Zhao, Carlos L. Arteaga, W. Fraser Symmans, Ben Ho Park, Brian L. Burnette +20 more

Association of treatment-emergent symptoms identified by patient-reported outcomes with adjuvant endocrine therapy discontinuation

npj Breast Cancer(2022)10.1038/s41523-022-00414-0

N/A

0DataRank · unranked

28 citations

Neha Verma, Amanda L. Blackford, Jennifer Lehman, Kelly Westbrook, David K. Lim +15 more

Factors Associated with Worsening Sexual Function During Adjuvant Endocrine Therapy in a Prospective Clinic-Based Cohort of Women with Early Stage Breast Cancer

Research Square(2022)10.21203/rs.3.rs-1685371/v1

N/A

0DataRank · unranked

0 citations

Amanda L. Blackford, Elissa Thorner, Jennifer Lehman, Claire Snyder, Vered Stearns +2 more

Phase I Study and Cell-Free DNA Analysis of T-DM1 and Metronomic Temozolomide for Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-0855

N/A

0DataRank · unranked

23 citations

Wei Zhang, Seth M. Steinberg, Darryl Nousome, Nicole Houston, Xiaolin Wu +22 more

Management of hormone receptor-positive, HER2-negative early breast cancer

Seminars in Oncology(2020)10.1053/j.seminoncol.2020.05.010

N/A

0DataRank · unranked

54 citations

Karen L. Smith, Vered Stearns, Elaine M. Walsh

Incorporation of emergent symptoms and genetic covariates improves prediction of aromatase inhibitor therapy discontinuation

JAMIA Open(2024)10.1093/jamiaopen/ooae006

N/A

0DataRank · unranked

1 citations

Vered Stearns, Amanda L. Blackford, Daniel L. Hertz, Karen L. Smith, James M. Rae +2 more

The impact of weight loss on physical function in overweight or obese breast cancer survivors.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.12053

N/A

0DataRank · unranked

3 citations

Cesar Augusto Santa-Maria, Amanda L. Blackford, David Lim, Ashley Carpenter, Karen L. Smith +6 more

Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.12069

N/A

0DataRank · unranked

0 citations

Ana Barac, Filipa Lynce, Xue Geng, Chau T. Dang, Anthony F. Yu +13 more